Evidence map›Paper›PMID 42747249›Full record

ReviewReproduction & fertility2026

Menopause following cancer treatment-induced menopause: unique considerations and current recommendations.

Gabriella Yongue, Zachary Nash, Kristyn Manley, Melanie C Davies, Shibani Nicum

Abstract readReview
In one paragraph

Review in Reproduction & fertility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gabriella YongueUniversity College London Cancer Institute , London, United Kingdom.ORCID 0000-0003-3865-0888
Zachary NashUniversity College London Hospital , London, United Kingdom.
Kristyn ManleyUniversity Hospitals Bristol NHS Foundation Trust , Bristol, United Kingdom.
Melanie C DaviesUniversity College London Hospital , London, United Kingdom.
Shibani NicumUniversity College London Cancer Institute , London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractMenopause following cancer treatment is an increasingly recognised component of survivorship yet remains under-addressed in clinical care. The aim of this review was to synthesise current evidence on menopause induced by cancer treatment, by bringing together current evidence on the underlying mechanisms, clinical manifestations, and management in the context of survivorship care. Evidence was evaluated from contemporary clinical studies, guideline recommendations, and emerging evidence across oncology and menopause research. Cancer treatment-induced menopause commonly results from surgical removal of the ovaries, follicular depletion from chemotherapy, and radiation-induced ovarian damage, and in some cases, it is chemically induced by gonadotrophin-releasing hormone agonists. The resulting symptom burden is often substantial, including vasomotor symptoms, mood disturbance, genitourinary syndrome, sexual dysfunction, fatigue, and cognitive difficulties that impair quality of life. In addition, premature or early menopause is associated with increased long-term health risks, including reduced bone density, cardiovascular disease, and adverse psychosocial outcomes, such as infertility and altered self-identity. Menopause symptoms can also overlap with treatment side effects, and management is often complex, requiring an individualised, multidisciplinary approach. Whilst hormone replacement therapy is effective, its use is limited by concerns regarding cancer recurrence in hormone-sensitive disease. As a result, non-hormonal and supportive strategies play a pivotal role in symptom management. Despite increasing recognition of the impact of menopause, there are few effective licensed therapies and access to specialist support and counselling is limited. Integrated menopause care that incorporates menopause management into oncology pathways offers a pragmatic approach, providing holistic, patient-centred strategies that balance long-term health risks with quality-of-life priorities. LAY SUMMARY: Cancer treatment, including surgery, chemotherapy, radiotherapy, or long-term therapies, can cause menopause, which is often sudden, resulting in severe symptoms that may overlap with treatment-related side effects. Menopause can therefore be complex to manage, and there may also be added concerns around promoting cancer recurrence. Menopause symptoms can include hot flushes, poor sleep, mood disturbance, vaginal dryness, reduced sexual well-being, fatigue, and problems with memory - these can all impact daily life. There may also be longer-term health impacts, including bone loss and cardiovascular disease. This review brings together current evidence to discuss why treatment-related menopause occurs and how it can be best managed. It highlights that, despite growing awareness, many cancer survivors do not receive adequate information, support, or treatment for these symptoms. As cancer survival improves, menopause care must become a central part of improved survivorship. Personalised approaches to menopause management have the potential to improve long-term health, well-being, and quality of life after cancer.

Indexed as

Antineoplastic AgentsMenopauseNeoplasmsFemaleHumansQuality of LifeAntineoplastic Agentscancer survivorshipcancer treatmentholistic managementiatrogenic menopausepremature ovarian insufficiency

Identifiers

PMID42747249
PMCPMC13663626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.